Adverse	adverse	O	O	O	O
cardiac	cardiac	O	O	O	O
effects	effects	O	O	O	O
during	during	O	O	O	O
induction	induction	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
cis-platin	cis-platin	O	O	O	O
and	and	O	O	O	O
5-fluorouracil	5-fluorouracil	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Survival	survival	O	O	O	O
for	for	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
advanced	advanced	O	O	O	O
head	head	O	O	OTHERS	I
and	and	O	O	OTHERS	I
neck	neck	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
and	and	O	O	O	O
esophageal	esophageal	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
is	is	O	O	O	O
poor	poor	O	O	O	O
with	with	O	O	O	O
radiotherapy	radiotherapy	O	O	O	O
and/or	and/or	O	O	O	O
surgery	surgery	O	O	O	O
.	.	O	O	O	O

Obviously	obviously	O	O	O	O
,	,	O	O	O	O
there	there	O	O	O	O
is	is	O	O	O	O
a	a	O	O	O	O
need	need	O	O	O	O
for	for	O	O	O	O
effective	effective	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
present	present	O	O	O	O
study	study	O	O	O	O
,	,	O	O	O	O
cis-platin	cis-platin	O	O	O	O
(	(	O	O	O	O
80	80	O	O	O	O
-	-	O	O	O	O
120	120	O	O	O	O
mg/m2BSA	mg/m2bsa	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
5-FU	5-fu	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
1000	1000	O	O	O	O
mg/m2BSA	mg/m2bsa	O	O	O	O
daily	daily	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
continuous	continuous	O	O	O	O
infusion	infusion	O	O	O	O
during	during	O	O	O	O
5	5	O	O	O	O
days	days	O	O	O	O
)	)	O	O	O	O
were	were	O	O	O	O
given	given	O	O	O	O
to	to	O	O	O	O
76	76	O	O	O	O
patients	patients	O	O	O	O
before	before	O	O	O	O
radiotherapy	radiotherapy	O	O	O	O
and	and	O	O	O	O
surgery	surgery	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
aim	aim	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
clarify	clarify	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
and	and	O	O	O	O
severity	severity	O	O	O	O
of	of	O	O	O	O
adverse	adverse	O	O	O	O
cardiac	cardiac	O	O	O	O
effects	effects	O	O	O	O
to	to	O	O	O	O
this	this	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

Before	before	O	O	O	O
treatment	treatment	O	O	O	O
all	all	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
cardiac	cardiac	O	O	O	O
evaluation	evaluation	O	O	O	O
and	and	O	O	O	O
during	during	O	O	O	O
treatment	treatment	O	O	O	O
serial	serial	O	O	O	O
ECG	ecg	O	O	O	O
recordings	recordings	O	O	O	O
were	were	O	O	O	O
performed	performed	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
pre-treatment	pre-treatment	O	O	O	O
evaluation	evaluation	O	O	O	O
,	,	O	O	O	O
signs	signs	O	O	O	O
of	of	O	O	O	O
cardiovascular	cardiovascular	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
were	were	O	O	O	O
found	found	O	O	O	O
in	in	O	O	O	O
33	33	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
43	43	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

During	during	O	O	O	O
treatment	treatment	O	O	O	O
,	,	O	O	O	O
adverse	adverse	O	O	O	O
cardiac	cardiac	O	O	O	O
effects	effects	O	O	O	O
were	were	O	O	O	O
observed	observed	O	O	O	O
in	in	O	O	O	O
14	14	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
18	18	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
mean	mean	O	O	O	O
age	age	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
patients	patients	O	O	O	O
was	was	O	O	O	O
the	the	O	O	O	O
same	same	O	O	O	O
as	as	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
entire	entire	O	O	O	O
group	group	O	O	O	O
,	,	O	O	O	O
64	64	O	O	O	O
years	years	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
was	was	O	O	O	O
not	not	O	O	O	O
higher	higher	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
signs	signs	O	O	O	O
of	of	O	O	O	O
cardiovascular	cardiovascular	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
than	than	O	O	O	O
in	in	O	O	O	O
those	those	O	O	O	O
without	without	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
pre-treatment	pre-treatment	O	O	O	O
evaluation	evaluation	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
most	most	O	O	O	O
common	common	O	O	O	O
signs	signs	O	O	O	O
of	of	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
were	were	O	O	O	O
chest	chest	O	DISEASE	OTHERS	I
pain	pain	O	DISEASE	OTHERS	I
,	,	O	O	O	O
ST-T	st-t	O	O	O	O
wave	wave	O	O	O	O
changes	changes	O	O	O	O
and	and	O	O	O	O
atrial	atrial	O	DISEASE	OTHERS	I
fibrillation	fibrillation	O	DISEASE	OTHERS	I
.	.	O	O	O	O

This	this	O	O	O	O
was	was	O	O	O	O
followed	followed	O	O	O	O
by	by	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
fibrillation	fibrillation	O	DISEASE	OTHERS	I
in	in	O	O	O	O
one	one	O	O	O	O
patient	patient	O	O	O	O
and	and	O	O	O	O
sudden	sudden	O	O	OTHERS	I
death	death	O	DISEASE	OTHERS	I
in	in	O	O	O	O
another	another	O	O	O	O
.	.	O	O	O	O

It	it	O	O	O	O
is	is	O	O	O	O
concluded	concluded	O	O	O	O
that	that	O	O	O	O
patients	patients	O	O	O	O
on	on	O	O	O	O
5-FU	5-fu	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
under	under	O	O	O	O
close	close	O	O	O	O
supervision	supervision	O	O	O	O
and	and	O	O	O	O
that	that	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
discontinued	discontinued	O	O	O	O
if	if	O	O	O	O
chest	chest	O	DISEASE	OTHERS	I
pain	pain	O	DISEASE	OTHERS	I
or	or	O	O	O	O
tachyarrhythmia	tachyarrhythmia	O	O	OTHERS	I
is	is	O	O	O	O
observed	observed	O	O	O	O
.	.	O	O	O	O

